IP Library Granted Patent US 10,905,767
Granted Patent B2
US 10,905,767 · App. 16/179,786 · Granted Feb 2, 2021

Oligonucleotide constructs and uses thereof

Inventors: Sergei Gryaznov (San Mateo, CA); Leonid Beigelman (San Mateo, CA); Theodore Yun (Burlingame, CA)
Assignee: Janssen BioPharma, Inc.
A61K47/543A61K9/0019A61K31/7088A61K39/39A61K47/14A61K47/22A61K47/26A61K47/545A61P31/20A61P35/00C12Q1/6876A61K2039/55561A61K2039/58A61K2039/585A61K2039/6018A61K2039/6025A61K2039/82C12N2730/10134
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,905,767
App. No.
16/179,786
Granted
Feb 2, 2021
Kind
B2
Abstract

Oligodeoxynucleotide-based immunostimulatory Toll-Like Receptor 9 (TLR9) agonists are described. Also described are compositions comprising the TLR9 agonists, methods of making the TLR9 agonists, and methods of using the TLR9 agonists to treat immune diseases, disorders or conditions, such as viral infections or cancer.

Claims (9)

1. An ODN construct having the following structure:

5′ Toco-po(HEG)po(HEG)po-TpsCpoGpsTpsCpoGpsTpsTpsTpsTpsGpsTpsCpoGpsTpsTpsTpsTpsGpsTpsCpoGpsTpsT 3′ (SEQ ID NO: 27);

wherein:

Toco represents tocopherol;

HEG represents ((CH 2 ) 2 O) 6 ;

po represents a phosphodiester linkage; and

ps represents a phosphorothioate linkage,

wherein the tocopherol is covalently linked to the (HEG) directly via the po linkage, or indirectly via a second linker that is linked to (HEG) directly via the po linkage.

2. A pharmaceutical composition comprising the ODN construct of claim 1 and a pharmaceutically acceptable carrier.

Assignments (5)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 10, 2023
From: JANSSEN PHARMACEUTICA NV
To: JANSSEN PHARMACEUTICALS, INC.
Reel/Frame 063602/0272 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 13, 2022
From: JANSSEN BIOPHARMA, LLC
To: JANSSEN PHARMACEUTICA NV
Reel/Frame 059693/0921 →
CHANGE OF NAME Recorded Dec 9, 2020
From: ALIOS BIOPHARMA, INC.
To: JANSSEN BIOPHARMA, INC.
Reel/Frame 055087/0702 →
CHANGE OF NAME Recorded Apr 20, 2020
From: ALIOS BIOPHARMA, INC.
To: JANSSEN BIOPHARMA, INC.
Reel/Frame 052440/0448 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 11, 2019
From: GRUAZNOV, SERGEI; BEIGELMAN, LEONID; YUN, THEODORE
To: ALIOS BIOPHARMA, INC.
Reel/Frame 048857/0929 →
Continuity (2)
Provisional Application 62580924 · Nov 2, 2017
Related Publication 20190160173A1 · May 30, 2019